Avanzanite Bioscience raises €32 million in a Series A funding round led by MVM Partners to accelerate its growth in the European rare disease market.

Target Information

Avanzanite Bioscience B.V., based in Amsterdam, Netherlands, is a rapidly growing specialty pharmaceutical company that focuses on addressing rare diseases. Established in 2022, Avanzanite has emerged as a leader in the commercialization of orphan medicines across Europe by offering a fully integrated approach to market access, pricing, and reimbursement. In just three years, the company has forged three strategic alliances and launched multiple rare disease medications, establishing itself as a vital partner for biotech and pharmaceutical innovators.

The company has experienced remarkable growth, with its revenue tripling year-on-year and exceeding a 20% increase quarter-on-quarter in Q3 2025. Avanzanite's current portfolio includes therapies in nephrology, ophthalmology, and hematology, with exclusive rights to distribute these medicines throughout the European Economic Area, the UK, and Switzerland.

Industry Overview

In recent years, the orphan drug market in Europe has witnessed significant growth, driven by an increasing focus on developing therapies for rare diseases. With more than 7,000 known rare diseases affecting millions of people, the deman